ResearcherLMU KlinikumNo recent work listed
Yonggan Xue
Matched on OpenAlex author ID A5055528510. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 3
- Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
- Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenoc… Co-author DOI 10.1053/j.gastro.2021.05.055↗
- FAPα in pancreatic stellate cells upregulated by TGFβ1: a novel insight into pancreatic cancer progress. Co-author DOI 10.21037/atm-20-2559↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Georg Beyer · 3 shared papers, 2020–2022 · strength 0.39
- Paper FAPα in pancreatic stellate cells upregulated by TGFβ1: a novel insight into pancreatic cancer progress. DOI 10.21037/atm-20-2559↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficie… DOI 10.1053/j.gastro.2021.05.055↗
- Julia V. Mayerle · 3 shared papers, 2020–2022 · strength 0.39
- Paper FAPα in pancreatic stellate cells upregulated by TGFβ1: a novel insight into pancreatic cancer progress. DOI 10.21037/atm-20-2559↗
- Paper Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. DOI 10.1172/jci.insight.151353↗
- Paper Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficie… DOI 10.1053/j.gastro.2021.05.055↗
- Ujjwal Mukund Mahajan · 2 shared papers, 2021–2022 · strength 0.21
- Katharina Lankes · 1 shared paper, 2022 · strength 0.11
- Christian Schneeweis · 1 shared paper, 2022 · strength 0.11
- Felix Orben · 1 shared paper, 2022 · strength 0.11
- Zonera Hassan · 1 shared paper, 2022 · strength 0.11
- Maximilian Reichert · 1 shared paper, 2022 · strength 0.11
- Bernhard Küster · 1 shared paper, 2022 · strength 0.11
- Lukas Krauß · 1 shared paper, 2022 · strength 0.11
- Christoph Schlag · 1 shared paper, 2022 · strength 0.11
- Carolin Schneider · 1 shared paper, 2022 · strength 0.11
- Roland Michael Schmid · 1 shared paper, 2022 · strength 0.11
- Janine Murr · 1 shared paper, 2022 · strength 0.11
- Roland Rad · 1 shared paper, 2022 · strength 0.11
- Günter Schneider · 1 shared paper, 2022 · strength 0.11
- Bo Kong · 1 shared paper, 2022 · strength 0.11
- Matthias Wirth · 1 shared paper, 2022 · strength 0.11
- Dieter Saur · 1 shared paper, 2022 · strength 0.11
- Ivonne Regel · 1 shared paper, 2021 · strength 0.10
- Michael Orth · 1 shared paper, 2021 · strength 0.10
- Kirsten Lauber · 1 shared paper, 2021 · strength 0.10
- Frank Ulrich Weiß · 1 shared paper, 2021 · strength 0.10
- Markus M. Lerch · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.